From the Journals

Sucralose damages DNA, linked to leaky gut: Study


 

FROM THE JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, PART B

A new study reveals health concerns about the sugar substitute sucralose so alarming that researchers said people should stop eating it and the government should regulate it more.

Sucralose is sold under the brand name Splenda and is also used as an ingredient in packaged foods and beverages.

The findings were published in the Journal of Toxicology and Environmental Health, Part B. The researchers conducted a series of laboratory experiments exposing human blood cells and gut tissue to sucralose-6-acetate. The findings build on previous research that linked sucralose to gut health problems.

The researchers found that sucralose causes DNA to break apart, putting people at risk for disease. They also linked sucralose to leaky gut syndrome, which means the lining of the intestines are worn down and become permeable. Symptoms are a burning sensation, painful digestion, diarrhea, gas, and bloating.

When a substance damages DNA, it is called genotoxic. Researchers have found that eating sucralose results in the body producing a substance called sucralose-6-acetate, which the new study now shows is genotoxic. The researchers also found sucralose-6-acetate in trace amounts in off-the-shelf products that are so high, they would exceed the safety levels currently allowed in Europe.

“It’s time to revisit the safety and regulatory status of sucralose because the evidence is mounting that it carries significant risks. If nothing else, I encourage people to avoid products containing sucralose,” researcher Susan Schiffman, PhD, adjunct professor of biomedical engineering at North Carolina State University, Raleigh, said in a statement. “It’s something you should not be eating.”

The FDA says sucralose is safe, describing it as 600 times sweeter than table sugar and used in “baked goods, beverages, chewing gum, gelatins, and frozen dairy desserts.”

“To determine the safety of sucralose, the FDA reviewed more than 110 studies designed to identify possible toxic effects, including studies on the reproductive and nervous systems, carcinogenicity, and metabolism,” the agency explained on its website. “The FDA also reviewed human clinical trials to address metabolism and effects on patients with diabetes.”

The study authors reported that they had no conflicts of interest.A version of this article first appeared on WebMD.com.

Recommended Reading

Pediatric IBD patients wrestle with lingering gut pain
MDedge Pediatrics
Mental health risks higher among young people with IBD
MDedge Pediatrics
Celebrity death finally solved – with locks of hair
MDedge Pediatrics
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
MDedge Pediatrics
Likely cause of mysterious hepatitis outbreak in children identified
MDedge Pediatrics
Children ate more fruits and vegetables during longer meals: Study
MDedge Pediatrics
Pediatric Crohn’s disease: Adalimumab plus methotrexate offers strong benefit
MDedge Pediatrics
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
MDedge Pediatrics
FDA approves Yuflyma as ninth adalimumab biosimilar
MDedge Pediatrics
APA launches online eating disorder assessment tool
MDedge Pediatrics